Valneva (NASDAQ:VALN – Get Rating) and Miromatrix Medical (NASDAQ:MIRO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Valneva and Miromatrix Medical, as reported by MarketBeat.

Valneva currently has a consensus price target of $25.00, indicating a potential upside of 95.31%. Miromatrix Medical has a consensus price target of $9.00, indicating a potential upside of 214.69%. Given Miromatrix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Miromatrix Medical is more favorable than Valneva.

Volatility & Risk

Valuation & Earnings

This table compares Valneva and Miromatrix Medical's gross revenue, earnings per share (EPS) and valuation.

Miromatrix Medical has lower revenue, but higher earnings than Valneva.

Profitability

This table compares Valneva and Miromatrix Medical's net margins, return on equity and return on assets.

Insider & Institutional Ownership

16.4% of Valneva shares are held by institutional investors. Comparatively, 15.5% of Miromatrix Medical shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.9% of Miromatrix Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Valneva beats Miromatrix Medical on 7 of the 11 factors compared between the two stocks.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

About Miromatrix Medical

(Get Rating)

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.